Amarin (AMRN) Competitors $15.01 +0.04 (+0.27%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$14.99 -0.02 (-0.13%) As of 09/12/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. XERS, ABCL, EVO, CVAC, COLL, PHVS, LENZ, ELVN, CALT, and ZYMEShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Xeris Biopharma (XERS), AbCellera Biologics (ABCL), Evotec (EVO), CureVac (CVAC), Collegium Pharmaceutical (COLL), Pharvaris (PHVS), LENZ Therapeutics (LENZ), Enliven Therapeutics (ELVN), Calliditas Therapeutics AB (publ) (CALT), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Its Competitors Xeris Biopharma AbCellera Biologics Evotec CureVac Collegium Pharmaceutical Pharvaris LENZ Therapeutics Enliven Therapeutics Calliditas Therapeutics AB (publ) Zymeworks Amarin (NASDAQ:AMRN) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership. Is AMRN or XERS more profitable? Xeris Biopharma has a net margin of -13.01% compared to Amarin's net margin of -47.22%. Xeris Biopharma's return on equity of 0.00% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets Amarin-47.22% -21.18% -15.00% Xeris Biopharma -13.01%N/A -8.00% Do insiders & institutionals have more ownership in AMRN or XERS? 22.3% of Amarin shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 2.0% of Amarin shares are owned by company insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable earnings and valuation, AMRN or XERS? Xeris Biopharma has lower revenue, but higher earnings than Amarin. Xeris Biopharma is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmarin$228.61M1.36-$82.18M-$3.67-4.09Xeris Biopharma$203.07M5.96-$54.84M-$0.21-35.67 Which has more risk and volatility, AMRN or XERS? Amarin has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Does the media refer more to AMRN or XERS? In the previous week, Xeris Biopharma had 9 more articles in the media than Amarin. MarketBeat recorded 11 mentions for Xeris Biopharma and 2 mentions for Amarin. Xeris Biopharma's average media sentiment score of 1.04 beat Amarin's score of 0.95 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend AMRN or XERS? Amarin currently has a consensus price target of $12.00, indicating a potential downside of 20.05%. Xeris Biopharma has a consensus price target of $7.08, indicating a potential downside of 5.43%. Given Xeris Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Xeris Biopharma is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryXeris Biopharma beats Amarin on 13 of the 16 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$310.41M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-4.0921.5775.4626.03Price / Sales1.36254.95466.5092.26Price / CashN/A44.4425.8129.91Price / Book0.649.6112.166.25Net Income-$82.18M-$53.29M$3.29B$270.76M7 Day Performance1.62%0.57%0.73%2.54%1 Month Performance-4.09%4.56%4.41%5.73%1 Year Performance25.08%10.44%62.61%25.85% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.5468 of 5 stars$15.01+0.3%$12.00-20.1%+25.1%$310.41M$228.61M-4.09360XERSXeris Biopharma2.7829 of 5 stars$7.77-1.0%$7.08-8.8%+160.1%$1.27B$203.07M0.00290News CoveragePositive NewsInsider TradeABCLAbCellera Biologics2.7474 of 5 stars$4.17-1.2%$8.00+91.8%+62.5%$1.26B$28.83M0.00500EVOEvotec1.68 of 5 stars$3.49+0.3%$5.40+54.7%-2.0%$1.24B$862.40M0.004,827CVACCureVac3.9987 of 5 stars$5.35-0.7%$6.83+27.7%+55.2%$1.21B$579.18M5.61880Short Interest ↑COLLCollegium Pharmaceutical3.7489 of 5 stars$37.75-1.5%$42.33+12.1%-0.5%$1.21B$631.45M6.60210Positive NewsPHVSPharvaris2.4902 of 5 stars$21.83-5.3%$34.00+55.7%+10.9%$1.21BN/A0.0030LENZLENZ Therapeutics1.6207 of 5 stars$39.63-5.6%$49.60+25.2%+89.1%$1.20BN/A0.00110Positive NewsELVNEnliven Therapeutics2.9617 of 5 stars$20.02-0.6%$41.20+105.8%-10.6%$1.19BN/A0.0050CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoverageZYMEZymeworks2.4237 of 5 stars$15.19+0.9%$21.43+41.1%+25.5%$1.14B$122.87M-10.13460Positive News Related Companies and Tools Related Companies Xeris Biopharma Alternatives AbCellera Biologics Alternatives Evotec Alternatives CureVac Alternatives Collegium Pharmaceutical Alternatives Pharvaris Alternatives LENZ Therapeutics Alternatives Enliven Therapeutics Alternatives Calliditas Therapeutics AB (publ) Alternatives Zymeworks Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRN Stock Alerts